ArticleBlood neoplasia2025
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications.Leukemia & lymphoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cytogenetic abnormalities influence the prognosis of multiple myeloma (MM). How these abnormalities associate with overall survival (OS) in European Americans (EAs) and African Americans (AAs) remains unclear. We collected data on fluorescence in situ hybridization targeting 17 cytogenetic abnormalities from 181 patients newly diagnosed with MM between 2010 and 2019. Vital status was ascertained using the National Death Index. Baseline clinical data were retrieved from electronic medical records. Established high-risk cytogenetic abnormalities (HRCAs) include t(4;14), t(14;16), t(14;20), del 17p, and gain/amplification of 1q. In each population, we evaluated the associations between cytogenetic abnormalities and OS. Among 55 AAs and 126 EAs, 65 deaths occurred (median follow-up: 5.8 years). The distribution of the abnormalities was similar between EAs and AAs. High-risk MM, characterized by HRCAs, was associated with worse OS in EAs (hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.3-5.5), but not AAs. Del 13q was associated with worse OS in both populations. Gain/amplification of 1q was associated with poorer OS in EAs (HR, 3.44; 95% CI, 1.3-9.3) but not AAs, whereas t(4;14) was associated with poorer OS in AAs (HR, 14.51; 95% CI, 2.3-92.3) but not EAs. These associations remained after controlling for prognostic factors or other HRCAs, highlighting the potential of population heterogeneity in the prognostic significance of cytogenetic abnormalities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.